Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tcr2 Therapeutics Inc
(NQ:
TCRR
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 31, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
1.490 (52)
Ask (Size)
1.630 (51)
Prev. Close
1.480
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
39,261,745
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
May 11, 2023
The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in...
Via
Benzinga
Recap: TCR2 Therapeutics Q1 Earnings
May 11, 2023
Via
Benzinga
Performance
More News
Read More
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 08, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
What To Know About Jefferies's Downgrade of TCR2 Therapeutics
March 09, 2023
Via
Benzinga
4 Analysts Have This to Say About TCR2 Therapeutics
March 09, 2023
Via
Benzinga
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
March 06, 2023
Via
Benzinga
Ribbon Communications And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
May 08, 2023
Via
Benzinga
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
April 26, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –
March 30, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
March 24, 2023
Via
Benzinga
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
March 23, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
March 09, 2023
Via
Benzinga
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
March 08, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023
March 08, 2023
Via
Benzinga
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
March 07, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
March 07, 2023
Via
Benzinga
Why Is TCR2 Therapeutics Stock Trading Higher Today?
March 06, 2023
Via
Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 06, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 06, 2023
Via
Benzinga
TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company
March 06, 2023
Via
Spotlight Growth
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
March 06, 2023
Via
InvestorPlace
TCRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of TCR² Therapeutics Inc. Is Fair to Shareholders
March 06, 2023
From
Halper Sadeh LLC
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 06, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.